Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + IDAC vs IDAC for AML Consolidation
NCT07537257Phase 3Enrolling by invitation
- Sponsor
- Guangdong Second Provincial General Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Guangdong Second Provincial General Hospital. Primary endpoint: Measurable residual disease negative rate at 56 days. Started Apr 2026; status: enrolling by invitation.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07537257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537257.